Furthermore, we describe distinct subclasses of RCC that can be defined by the activation of the MEK and mTOR pathways, have clinically distinct prognosis, and would be predicted to have differential responses to MEK and mTOR kinase inhibition. This evidence concerns the gene MAP2K7 and renal cell carcinoma.